AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million

Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.

More from Archive

More from Pink Sheet